The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration

Wong, Tien Yin; Chakravarthy, Usha; Klein, Michael L.; Mitchell, Paul; Zlateva, Gergana; Buggage, Ronald; Fahrbach, Kyle; Probst, Corey; Sledge, Isabella

doi:10.1016/j.ophtha.2007.03.008

Cited by 531 publications

(349 citation statements)

References 85 publications

Supporting

Mentioning

328

Contrasting

Unclassified

Order By: Relevance

“…1,3,5 The lower rate of 8.7% of patients developing nAMD in second eyes found in our study was probably due to the variable length of follow-up, which was inevitable in such a retrospective study. Nevertheless, the quantification of the proportion of patients with bilateral involvement in this study serves to highlight not only the burden on health care providers, with about 1 in 10 patients needing intensive treatment and visual rehabilitation for bilateral visual loss at any one time in a service of this nature but also the impact of visual loss on a sizeable proportion of elderly individuals.…”

Section: Discussionmentioning

confidence: 49%

See 1 more Smart Citation

Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration

Amissah-Arthur

Panneerselvam

Narendran

et al. 2011

Eye

View full text Add to dashboard Cite

Aim To describe the frequency of neovascular age-related macular degeneration (nAMD) in second eyes of patients undergoing ranibizumab therapy in their first eye and to evaluate the patterns of optical coherence tomography (OCT) abnormalities in fellow eyes before nAMD. Method Patients who developed choroidal neovascularization (CNV) in the second eye while on treatment for the first eye were identified. OCT scans of the second eyes, performed before the onset of CNV, were retrospectively examined and graded. Frequency of second eye involvement was estimated and patterns of progression of OCT abnormalities were described and classified. Results In all, 65 out of 749 consecutive patients required ranibizumab in their second eye for treatment-naïve nAMD over a 2-year period. The mean interval from commencement of ranibizumab in first eye to conversion in second eye was 12 months (2-35.5 months). There were three patterns of CNV development: group A (12%, n ¼ 8) had no OCT abnormalities in the second eye just before developing CNV; group B (38%, n ¼ 25) had no abnormalities at baseline but developed OCT changes more than one visit before conversion and group C (50%, n ¼ 32) had OCT changes from baseline, which did not progress until just before conversion. ConclusionPatients with retinal pigment epithelial elevation without sub-retinal fluid on OCT in their fellow eyes have a high risk of progression to require therapy within a 2-year period. An anticipatory approach may be warranted, but a small group with completely normal OCT appearances can still develop lesions between visits.

show abstract

Section: Discussionmentioning

confidence: 49%

“…In such patients who present with unilateral nAMD, the risk of second eye involvement in their good, fellow eyes has been estimated to be between 2 and 30% per year. 1,[3][4][5][6] This means that, in our clinical practice, a high proportion of patients present to us with unaffected, fellow eyes that are at a high risk of developing nAMD.…”

Section: Introductionmentioning

confidence: 99%

Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration

Amissah-Arthur

Panneerselvam

Narendran

et al. 2011

Eye

View full text Add to dashboard Cite

show abstract

“…Noticeable declines in visual function do not occur until advanced forms of AMD, which may take years (Buschini et al 2015). Advanced AMD takes two primary forms defined by whether neovascularization occurs; geographic atrophy (GA) (Buschini et al 2015) presents with regional RPE cell death without blood vessel intrusion, while exudative (i.e., wet) AMD does (Wong et al 2008). Over three-quarters of legal blindness results from wet AMD (Buschini et al 2015), but GA accounts for the vast majority of advanced AMD cases ).…”

Section: Complement Inhibitors For Armdmentioning

confidence: 99%

Corticosteroids and Anti-Complement Therapy in Retinal Diseases

Narayanan

Kuppermann

2016

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

“…In dry ARMD, deposits called drusen accumulate between the retina and the choroid, and slow degeneration of RPE and later photoreceptors leads to localized "geographic" atrophy and central vision loss. In wet ARMD, new, leaky blood vessels grow up from the choroid behind the retina, leading to acute vision loss (Wong et al, 2008). Retinitis pigmentosa is a collection of genetic diseases that generally start with night blindness and then continues on to tunnel vision, reflecting a pathology that affects rod photoreceptors in the peripheral retina earlier in the disease (Sahel et al).…”

Section: Pathologymentioning

confidence: 99%